<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34964421</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>75</StartPage>
          <EndPage>88</EndPage>
          <MedlinePgn>75-88</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2021.2018523</ELocationID>
        <Abstract>
          <AbstractText>Breast cancer is one of the most common types of cancer in female patients with high morbidity and mortality. Multi-drug chemotherapy has significant advantages in the treatment of malignant tumors, especially in reducing drug toxicity, increasing drug sensitivity and reducing drug resistance. The objective of this research is to fabricate lipid nanoemulsions (LNs) for the co-delivery of PTX and docosahexaenoic acid (DHA) with folic acid (FA) decorating (PTX/DHA-FA-LNs), and investigate the anti-tumor activity of the PTX/DHA-FA-LNs against breast cancer both <i>in vitro</i> and <i>in vivo</i>. PTX/DHA-FA-LNs showed a steady release of PTX and DHA from the drug delivery system (DDS) without any burst effect. Furthermore, the PTX/DHA-FA-LNs exhibited a dose-dependent cytotoxicity and a higher rate of apoptosis as compared with the other groups in MCF-7 cells. The cellular uptake study revealed that this LNs were more readily uptaken by MCF-7 cells and M2 macrophages <i>in vitro</i>. Additionally, the targeted effect of PTX/DHA-FA-LNs was aided by FA receptor-mediated endocytosis, and its cytotoxicity was proportional to the cellular uptake efficiency. The anti-tumor efficiency results showed that PTX/DHA-FA-LNs significant inhibited tumor volume growth, prolonged survival time, and reduced toxicity when compared with the other groups. These results indicated that DHA increases the sensitivity of tumor cells and tumor-associated macrophages (ATM2) to PTX, and synergistic effects of folate modification in breast cancer treatment, thus PTX/DHA-FA-LNs may be a promising nanocarrier for breast cancer treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Tingfei</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chu</LastName>
            <ForeName>Weiwei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Yuanzi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Shanshan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Jihui</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004655">Emulsions</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>935E97BOY8</RegistryNumber>
          <NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OJE5810C4F</RegistryNumber>
          <NameOfSubstance UI="C528070">docosahexaenoyl-paclitaxel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004655" MajorTopicYN="N">Emulsions</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067996" MajorTopicYN="N">RAW 264.7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000084582" MajorTopicYN="N">Tumor-Associated Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Paclitaxel (PTX)</Keyword>
        <Keyword MajorTopicYN="N">breast cancer</Keyword>
        <Keyword MajorTopicYN="N">docosahexaenoic acid (DHA)</Keyword>
        <Keyword MajorTopicYN="N">folic acid (FA)</Keyword>
        <Keyword MajorTopicYN="N">lipid nanoemulsions (LNs)</Keyword>
        <Keyword MajorTopicYN="N">multi-drug chemotherapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>8</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34964421</ArticleId>
        <ArticleId IdType="pmc">PMC8735879</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2021.2018523</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adkins Y, Kelley DS. (2010). Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem
21:781–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20382009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albanese A, Tang PS, Chan WC. (2012). The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng
14:1–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22524388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alibolandi M, Ramezani M, Sadeghi F, et al.  (2015). Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro. Int J Pharm
479:241–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25529433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alibolandi M, Rezvani R, Farzad SA, et al.  (2017). Tetrac-conjugated polymersomes for integrin-targeted delivery of camptothecin to colon adenocarcinoma in vitro and in vivo. Int J Pharm
532:581–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28935257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assaraf YG, Leamon CP, Reddy JA. (2014). The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat
17:89–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25457975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao H, Dan Z, He X, et al.  (2016). Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano
10:7738–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27454827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao X, Tan T, Zhu D, et al.  (2020). Paclitaxel-loaded macrophage membrane camouflaged albumin nanoparticles for targeted cancer therapy. Int J Nanomedicine
15:1915–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7090179</ArticleId>
            <ArticleId IdType="pubmed">32256068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardoso F, Kyriakides S, Ohno S, et al.  (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
30:1194–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31161190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Bathula SR, Yang Q, et al.  (2010). Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol
130:2790–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20686495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dehaini D, Wei X, Fang RH, et al.  (2017). Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater
29:1606209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5469720</ArticleId>
            <ArticleId IdType="pubmed">28199033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabian CJ, Kimler BF, Hursting SD. (2015). Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Res
17:62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4418048</ArticleId>
            <ArticleId IdType="pubmed">25936773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fasehee H, Dinarvand R, Ghavamzadeh A, et al.  (2016). Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations. J Nanobiotechnol
14:32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4839071</ArticleId>
            <ArticleId IdType="pubmed">27102110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco MS, Roque MC, de Barros ALB, et al.  (2019). Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model. Biomed Pharmacother
109:1728–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30551427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gawde KA, Sau S, Tatiparti K, et al.  (2018). Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Colloids Surf B Biointerfaces
167:8–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29625422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gohler S, Da Silva Filho MI, Johansson R, et al.  (2017). Functional germline variants in driver genes of breast cancer. Cancer Causes Control
28:259–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28238063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hazeldine J, Harris P, Chapple IL, et al.  (2014). Impaired neutrophil extracellular trap formation: a novel defect in the innate immune system of aged individuals. Aging Cell
13:690–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4326942</ArticleId>
            <ArticleId IdType="pubmed">24779584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu J, Yuan XW, Wang F, et al.  (2021). The progress and perspective of strategies to improve tumor penetration of nanomedicines. Chin Chem Lett
32:1341–7.</Citation>
        </Reference>
        <Reference>
          <Citation>Jin X, Zhang J, Jin X, et al.  (2020). Folate receptor targeting and cathepsin B-sensitive drug delivery system for selective cancer cell death and imaging. ACS Med Chem Lett
11:1514–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7430950</ArticleId>
            <ArticleId IdType="pubmed">32832017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalifa AM, Elsheikh MA, Khalifa AM, et al.  (2019). Current strategies for different paclitaxel-loaded nano-delivery systems towards therapeutic applications for ovarian carcinoma: a review article. J Control Release
311–312:125–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31476342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumari P, Ghosh B, Biswas S. (2016). Nanocarriers for cancer-targeted drug delivery. J Drug Target
24:179–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26061298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, et al.  (2008). Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol
26:442–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18571753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y, Wang Y, Song B. (2019). Griffipavixanthone induces apoptosis of human breast cancer MCF-7 cells in vitro. Breast Cancer
26:190–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30259331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maheo K, Vibet S, Steghens JP, et al.  (2005). Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med
39:742–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16109304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammad RM, Muqbil I, Lowe L, et al.  (2015). Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol
35:S78–S103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4720504</ArticleId>
            <ArticleId IdType="pubmed">25936818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monteiro CAP, Oliveira A, Silva RC, et al.  (2020). Evaluating internalization and recycling of folate receptors in breast cancer cells using quantum dots. J Photochem Photobiol B
209:111918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32531690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mouradian M, Kikawa KD, Dranka BP, et al.  (2015). Docosahexaenoic acid attenuates breast cancer cell metabolism and the Warburg phenotype by targeting bioenergetic function. Mol Carcinog
54:810–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24729481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muhamad N, Plengsuriyakarn T, Na-Bangchang K. (2018). Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine
13:3921–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6038858</ArticleId>
            <ArticleId IdType="pubmed">30013345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mussi SV, Sawant R, Perche F, et al.  (2014). Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells. Pharm Res
31:1882–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24522814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mussi SV, Silva RC, Oliveira MC, et al.  (2013). New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci
48:282–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23178339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niu F, Yan J, Ma B, et al.  (2018). Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy. Biomaterials
167:132–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5889738</ArticleId>
            <ArticleId IdType="pubmed">29571049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oroojalian F, Babaei M, Taghdisi SM, et al.  (2018). Encapsulation of thermo-responsive gel in pH-sensitive polymersomes as dual-responsive smart carriers for controlled release of doxorubicin. J Control Release
288:45–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30171978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J, Choi Y, Chang H, et al.  (2019). Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics
9:8073–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6857053</ArticleId>
            <ArticleId IdType="pubmed">31754382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponde NF, Zardavas D, Piccart M. (2019). Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol
16:27–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30206303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin T, Xu X, Zhang Z, et al.  (2020). Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer. Nanotechnology
31:365101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32434167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren X, Wang N, Zhou Y, et al.  (2021). An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway. Acta Biomater
124:179–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33524560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rescigno T, Capasso A, Tecce MF. (2016). Effect of docosahexaenoic acid on cell cycle pathways in breast cell lines with different transformation degree. J Cell Physiol
231:1226–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26480024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serini S, Ottes Vasconcelos R, Nascimento Gomes R, et al.  (2017). Protective effects of omega-3 PUFA in anthracycline-induced cardiotoxicity: a critical review. Int J Mol Sci
18:2689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5751291</ArticleId>
            <ArticleId IdType="pubmed">29231904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen M, Huang Y, Han L, et al.  (2012). Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. J Control Release
161:884–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22587941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siddiqui RA, Harvey KA, Xu Z, et al.  (2011). Docosahexaenoic acid: a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects. Biofactors
37:399–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22038684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. (2020). Cancer statistics, 2020. CA Cancer J Clin
70:7–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31912902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun H, Su J, Meng Q, et al.  (2016). Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv Mater
28:9581–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27628433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung H, Ferlay J, Siegel RL, et al.  (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
71:209–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33538338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang H, Chen J, Wang L, et al.  (2020). Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer. Int J Pharm
573:118806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31678519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Untch M, Jackisch C, Schneeweiss A, et al.  (2016). Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol
17:345–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26869049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Li D, Cang H, et al.  (2019). Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment. Cancer Med
8:4709–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6712467</ArticleId>
            <ArticleId IdType="pubmed">31222971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang TM, Chen CJ, Lee TS, et al.  (2011). Docosahexaenoic acid attenuates VCAM-1 expression and NF-κB activation in TNF-α-treated human aortic endothelial cells. J Nutr Biochem
22:187–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20573493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong RS. (2011). Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res
30:87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3197541</ArticleId>
            <ArticleId IdType="pubmed">21943236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Q, Yang Z, Nie Y, et al.  (2014). Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett
347:159–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24657660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao Q, Gutierrez DC, Hoang NH, et al.  (2017). Efficient codelivery of paclitaxel and curcumin by novel bottlebrush copolymer-based micelles. Mol Pharm
14:2378–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28605595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu W, Hu C, Gao H. (2021). Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages. Adv Drug Deliv Rev
178:113909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34352354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Miao J, Du YZ, et al.  (2008). Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm
348:137–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17714896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Sun X, Li J, et al.  (2011). Lipid nanoemulsions loaded with doxorubicin–oleic acid ionic complex: characterization, in vitro and in vivo studies. Pharmazie
66:496–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21812324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng X, Xie JZ, Zhang X, et al.  (2021). An overview of polymeric nanomicelles in clinical trials and on the market. Chin Chem Lett
32:243–57.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
